PathologybioRxiv
Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate model
C. Herate, R. Marlin, F. Touret…·R. Le Grand
This study shows Sotrovimab remains effective against SARS-CoV-2 BQ.1.1 in a non-human primate model, as measured by reduced viral replication.
DOI 10.1016/j.heliyon.2023.e16664